COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 108 participants.

Also called NCT02744677

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 108 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02744677
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT02744677. Non-randomized; no masking; primary purpose treatment. Start 2016-07-05 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
Condition
Complex Congenital Heart Defect
Condition
Dysfunctional RVOT Conduit
Condition
Pulmonary Valve Insufficiency
Condition
Pulmonary Valve Degeneration
Intervention (Device)
SAPIEN 3/SAPIEN 3 Ultra RESILIA THV
Intervention (Device)
SAPIEN 3 THV
Intervention (Device)
SAPIEN 3 Ultra RESILIA THV
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct02744677
Content hash
64ed655104e3d66235ba6f9c89c070d58a6834ca1e764229c22ca00d5faf7f4b